Amicus Therapeutics to Present at Cowen and Company 35th Annual Health Care Conference

CRANBURY, N.J., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics FOLD, a biopharmaceutical company at the forefront of rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the Cowen and Company 35th Annual Health Care Conference in Boston, MA on Monday, March 2, 2015 at 4:50 p.m. ET.

A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.

About Amicus Therapeutics

Amicus Therapeutics FOLD is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, as well as next-generation enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and MPS-1.

FOLD–G